<DOC>
	<DOCNO>NCT02796118</DOCNO>
	<brief_summary>The objective study evaluate safety pharmacokinetics ASP2151 multiple oral dose ASP2151 healthy non-elderly male elderly male Japanese subject , compare pharmacokinetics ASP2151 healthy non-elderly male elderly male Japanese subject .</brief_summary>
	<brief_title>Study Evaluate Safety Pharmacokinetics ASP2151 Healthy Non-elderly Elderly Subjects</brief_title>
	<detailed_description />
	<criteria>Body weight : ≥50.0 kg &lt; 85.0 kg Body mass index ( BMI ) : ≥17.6 &lt; 26.4 kg/m2 Subjects complication diseases Subjects history hepatic disease Subjects history heart disease Subjects history respiratory disease Subjects history alimentary disease Subjects history renal disease Subjects history cerebrovascular disorder Subjects history malignant tumor Subjects history drug allergy allergies disorder exclude pollinosis Subjects history drug dependency alcohol dependence syndrome Subjects develop genital herpes herpes zoster within 90 day initial dosing Subjects meet criterion laboratory test Subjects received medication within 14 day initial dose . Subjects receive investigational drug clinical trial postmarketing study within 120 day screen initial dose Excessive alcohol drink smoke habit Subjects previously receive administration ASP2151 ( include placebo ) Abnormalities detect ophthalmological examination Subjects deviate normal range standard 12lead ECG screening</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy non-elderly elderly subject</keyword>
	<keyword>ASP2151</keyword>
	<keyword>Safety</keyword>
</DOC>